Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
JU INSIGHT Platelet-rich Plasma for Erectile Dysfunction: A Randomized, Double-blind, Placebo-controlled Trial
By: Thomas A. Masterson, MD, University of Miami Miller School of Medicine, Florida; Manuel Molina, MD, University of Miami Miller School of Medicine, Florida; Braian Ledesma, MD, University of Miami Miller School of Medicine, Florida; Isaac Zucker, MD, University of Miami Miller School of Medicine, Florida; Russell Saltzman, University of Miami Miller School of Medicine, Florida; Emad Ibrahim, MD, University of Miami Miller School of Medicine, Florida; Sunwoo Han, PhD, University of Miami Miller School of Medicine, Florida; Isildinha M. Reis, PhD, University of Miami Miller School of Medicine, Florida; Ranjith Ramasamy, MD, University of Miami Miller School of Medicine, Florida | Posted on: 20 Jul 2023
Masterson TA, Molina M, Ledesma B, et al. Platelet-rich plasma for the treatment of erectile dysfunction: a prospective, randomized, double-blind, placebo-controlled clinical trial. J Urol. 2023;210(1):154-161.
Study Need and Importance
Erectile dysfunction (ED) is a common problem in men, and there is increasing interest in restorative therapies such as platelet-rich plasma (PRP) that may be capable of reversing underlying pathology and reestablishing natural spontaneous erections.
What We Found
In this prospective, randomized, double-blind, placebo-controlled clinical trial, we evaluated the safety and clinical efficacy of PRP for ED. Men with mild to moderate ED were sequentially randomized 1:1 to receive PRP or placebo, and regardless of randomization, all patients underwent 2 sessions of intracavernosal injections separated by 28±7 days. The study found that PRP did not significantly improve erectile function compared to placebo at 1 month after the second injection. PRP injection was well tolerated with no significant adverse events.
Limitations
The limitations of this study include a small sample size and a short follow-up period.
Interpretation for Patient Care
The interpretation of the results should be made with caution, and further studies are needed to determine the long-term efficacy and safety of PRP for ED. Nonetheless, the study’s objective data contribute to the ongoing research on restorative therapies for ED and can be a valuable resource for practicing urologists who are considering restorative therapies as treatment options, as well as for the many men’s health clinics that advertise these therapies without any supporting data.
advertisement
advertisement